Tradestie Institutional Equity Comparison Engine

BEAM vs LCTX โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-19 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

LCTX Overall Edge

LCTX Captures Institutional Edge (3โ€“1 Pillars ยท 7โ€“2 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Lineage Cell Therapeutics, Inc. (LCTX) driven by superior Valuation, Growth & Margin, Momentum & Technical while BEAM counters with relative strength in Options & Structure. Fundamentally, BEAM trades at N/M Forward P/E with -267.7% operating margin (-96.8% YoY revenue) versus LCTX at 30.7x Forward P/E and -280.3% operating margin (-61.0% YoY). In options structure, BEAM sits in BREAKDOWN (19th %ile IV; Dealer Gamma Walls on Pro) against LCTX sits in BREAKDOWN (100th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner LCTX
BEAM N/M vs LCTX 30.7x Fwd P/E
Growth & Margin Winner LCTX
Op Margin -267.7% vs -280.3% ยท YoY -96.8% vs -61.0%
Momentum & Technical Winner LCTX
1Y -4.5% vs -53.7% ยท 52W Pos 4% vs 4%
Options & Structure Winner BEAM
BREAKDOWN (19th %ile IV) vs BREAKDOWN (100th %ile IV)
BEAM NASDAQ
Beam Therapeutics Inc. Common Stock
Biological Products, (No Disgnostic Substances)
$20.94
-0.33% 1D
Market Cap $2.2B
1M Return -15.7%
1Y Return -4.47%
Forward P/E N/M
Unified AI Score
57.3 / 100 HOLD
Tech 63.0 Fund 60.0 Flow 68.0 Mom 60.0
LCTX NYSE American
Lineage Cell Therapeutics, Inc.
Biological Products, (No Disgnostic Substances)
$0.82
-2.21% 1D
Market Cap $212.1M
1M Return -13.82%
1Y Return -53.67%
Forward P/E 30.7x
Unified AI Score
58.9 / 100 HOLD
Tech 65.0 Fund 54.0 Flow 65.0 Mom 45.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: BEAM -4.47% LCTX -53.67% Spread: +49.2 pp (BEAM Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period BEAM Revenue LCTX Revenue BEAM Op. Margin LCTX Op. Margin Margin Edge
FY2018 N/A $0M N/A -837.9% LCTX
FY2019 $0M $0M -417522.2% -1106.0% LCTX
FY2020 $0M $0M -553166.7% -1448.4% LCTX
FY2021 $50M $0M -757.0% -1133.6% BEAM
FY2022 $60M $10M -555.6% -153.2% LCTX
FY2023 $380M $10M -46.7% -276.5% BEAM
FY2024 $60M $10M -654.3% -226.1% LCTX
FY2025 $140M $10M -274.6% -251.6% LCTX

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: BEAM (2) vs LCTX (7)
Institutional Metric BEAM LCTX Criterion Row Winner
Market Capitalization Scale $2.2B $212.1M Larger Scale BEAM
Trailing P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Forward P/E Ratio Valuation N/M 30.7x Lower Multiple LCTX
Revenue Growth (YoY) Growth -96.8% -61.0% Higher Growth LCTX
Operating Margin (TTM) Profitability -267.7% -280.3% Higher Margin BEAM
Net Profit Margin Profitability -73.9% 16.2% Higher Margin LCTX
Return on Equity (ROE) Capital Efficiency -11.3% 4.3% Higher ROE LCTX
52-Week Range Position Momentum 4% ($20โ€“$38) 4% ($1โ€“$2) Stronger Trend Tie
Beta / 30D Volatility Risk Regime 2.24ฮฒ ยท 86% Vol 1.36ฮฒ ยท 79% Vol Lower Realized Risk LCTX
Unified Institutional Score Composite Signal 57.3 / 100 (HOLD) 58.9 / 100 (HOLD) Higher Composite LCTX

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full BEAM vs LCTX Buy Guide
BEAM BREAKDOWN
106d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 19th %ile
IV Regime Compressed (<25th %ile)
Live BEAM Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
LCTX BREAKDOWN
6d in phase ยท OBV DISTRIBUTION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 100th %ile
IV Regime Extreme (>80th %ile)
Live LCTX Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither BEAM nor LCTX registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.